Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate...

Published on 18 Feb 2025 on Benzinga · via Yahoo Finance

On Tuesday, Biogen Inc. (NASDAQ:BIIB) and Stoke Therapeutics, Inc. (NASDAQ:STOK) collaborated to...

Read the rest of the article

Start tracking your investments with Statfolio

Biogen Inc.'s (NASDAQ:BIIB) recent earnings report didn't offer any surprises, with the shares...

Simply Wall St. · via Yahoo Finance 19 Feb 2025

On Tuesday, Biogen Inc. (NASDAQ:BIIB) and Stoke Therapeutics, Inc. (NASDAQ:STOK) collaborated to...

Benzinga · via Yahoo Finance 18 Feb 2025

Biogen's SWOT analysis: stock faces challenges amid pipeline potential

Investing.com 18 Feb 2025

Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the compa...

The Business Journals 12 Feb 2025

Biogen Inc. (NASDAQ:BIIB), currently valued at $19.15 billion by market capitalization, reported ...

Investing.com 12 Feb 2025

We recently published a list of Jim Cramer’s Thoughts on These 7 Stocks. In this article, we are...

Insider Monkey · via Yahoo Finance 1 Feb 2025

Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right...

Zacks · via Yahoo Finance 29 Jan 2025

Sage Therapeutics turns down Biogen's offer to buy the remaining stake in the company and is...

Zacks · via Yahoo Finance 28 Jan 2025

The FDA's approval is based on simulation data from multiple studies showing that maintenance dos...

Zacks · via Yahoo Finance 27 Jan 2025

Sage Therapeutics, Inc. (NASDAQ:SAGE) stock climbed 2.5% today, reflecting investor sentiment aft...

Investing.com 27 Jan 2025